The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. [electronic resource]
Producer: 20191125Description: 219 p. digitalISSN:- 1756-9966
- Acrylamides -- administration & dosage
- Aniline Compounds -- administration & dosage
- Animals
- Brain Neoplasms -- drug therapy
- Cell Line, Tumor
- Cell Movement
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- drug effects
- ErbB Receptors -- antagonists & inhibitors
- Glioblastoma -- drug therapy
- Humans
- MAP Kinase Signaling System -- drug effects
- Male
- Mice
- Protein Kinase Inhibitors -- administration & dosage
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.